• Select Network surpasses 120 active sites with expansion into additional US states
• Dr. Chirag Patel commercial project confirmed for new lower limb metrics for NCAA, elite sport, and military
• European clinical landmark: dorsaVi sensors selected for SEROMA study on Axial Spondyloarthritis

dorsaVi Ltd (ASX: DVL) has announced a series of commercial and clinical milestones that represent a meaningful acceleration in the company's commercial trajectory and technology leadership. The announcements span two distinct but strategically connected agreements, one in elite US sport and one in European clinical research, united by the common theme of 'Intelligence at the Ultra Edge'. Both are underpinned by dorsaVi's proprietary Onboard Sensor Processing (OSP) capability, which transforms its wearable sensors from data-capture devices into real-time intelligent systems capable of generating validated, clinical-grade metrics at the point of measurement. The Select Medical physical therapy network has now surpassed 100 active sites across the United States, with targeted expansion into new states currently underway. dorsaVi has also formalised commercial terms with Dr. Chirag Patel, a prominent US Foot and Ankle Physician, Surgeon, and Resident Injury Expert for ESPN, for an 8-month project to develop a new premium lower-limb analytics module within the ViMove+ platform. Additionally, dorsaVi's sensors and ViMove+ software have been selected as the technology platform for the SEROMA project, a landmark European clinical study investigating objective outcome measures for Axial Spondyloarthritis (axSpA). The company's investment in neuromorphic computing and Resistive RAM (RRAM) is directly relevant to the commercial pipeline being built today, as these technologies will enable a step-change in OSP performance. Beyond the clinical and sporting markets, dorsaVi sees a longer-horizon opportunity in the role of high-quality human movement data in the development of humanoid robotics.

The combined contracted revenue from the new agreements with Dr Patel and the SEROMA project exceeds A$200,000.